Bim is up in the air, CB is in phase 2, Replicel will be in Japan and asian markets by 2018 (they are claiming it's a full cure), Setipiprant (PGD2 blocker backed by Cotsarelis) will be entering phase 2 in Dec/Jan. SM04554 will be finishing phase 2 in September. I'm really excited for SM because of all the "breakthrough discoveries" regarding the WNT pathway and hair loss. All research seems to point to activating the WNT pathway as the best chance for regrowth. They recruited 300 participants (the max for phase 2), and only norwood 4-6. Samumed is also backed by Pfizer, and are the leading company developing drugs for activating or inhibiting the WNT pathway.
We won't have anything this yr, but 2016 an 2017 should be very good indeed.
We won't have anything this yr, but 2016 an 2017 should be very good indeed.
Comment